Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 1 of 63   
Protocol  
A Phase I, Open -label, Randomized, Parallel-arm, Single -dose Study to 
Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 
Administered Subcutaneously in Healthy Japanese and Caucasian Subjects  
Protocol Status: Final 
Protocol Date: 24 August  2021 
Protocol Version: 2.0 
Investigational Product: AMG 133 
Amgen Protocol Reference Number: 20200290  
Labcorp Drug Development Study Number: 8473020 
Sponsor: 
Amgen  Inc. 
One Amgen Center Drive Thousand Oaks, California 91320, USA 
This protocol was developed, reviewed, and approved in accordance with Labcorp 
Drug Development’s standard operating procedures. This format and content of this protocol is aligned with Good Clinical Practice: Consolidated Guidance (ICH E6). 
Study ID: [REMOVED]
This NCT number has been applied to the document
for purposes of posting on Clinicaltrials.gov
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 2 of 63 Confidentiality Notice  
This document contains confidential information of Amgen Inc. 
This document must not be disclosed to anyone other than the site study staffs and 
members of the Institutional Review Board/Independent Ethics Committee/Institutional Scientific Review Board or equivalent.  
The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc.  
If you have questions regarding how this document may be used or shared, call the Amgen Medical Information number: US sites, 1- 800-77- AMGEN; Canadian sites, 
1-866-50-AMGEN; Amgen’s general number in the US, 1-805-447-1000.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 3 of 63 INVESTIGATOR AGREEMENT  
I have read the protocol entitled “A Phase I, Open -label, Randomized, Parallel -arm, Single -dose 
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered 
Subcutaneously in Healthy Japanese and Caucasian Subjects” and agree to conduct the study as described herein.  
I agree to comply with the International Council for Harmonisation (ICH) Tripartite Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable national or regional regulations/guidelines.  
I agree to ensure that the confidential information contained in this document will not be used for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior written consent of Amgen Inc. 
 _______________________________ Signature  _______________________________ ____________________________ 
Name of Investigator  Date (DD Month YYYY)  
 _______________________________ Title and Role of Investigator  _______________________________ Institution Name  
 _______________________________ Address and Telephone Number of I nstitution  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01 , 24 August 2021 Page 4 of 63 STUDY IDENTIFICATION 
Sponsor Amgen Inc.  
One Amgen Center Drive  
Thousand Oaks, California 91320, USA  
Sponsor’s Study 
Contact Director, Clinical Pharmacology  
Amgen Inc. One Amgen Center Drive  
Thousand Oaks, California 91320, USA  
Tel:Email:
Medical Monitor  
  MD 
Medical Director  
Labcorp Drug Development Clinical Pharmacology Services 3301 Kinsman Boulevard Madison, Wisconsin 53704, USA Tel: (Office):Email:
Sponsor’s Study Manager  Global Early Clinical Development Manager  
Amgen Inc. One Amgen Center Drive  
Thousand Oaks, California 91320, USA  
Tel:
Email:
Labcorp Drug 
Development PM  MBA 
Project Manager  
Labcorp Drug Development Clinical Pharmacology Services  3301 Kinsman Boulevard  Madison, Wisconsin 53704, USA  
Tel:
Email:
Statistician  MS 
Labcorp Drug Development Clinical Pharmacology Services 
3301 Kinsman Boulevard Madison, Wisconsin 53704, USA TelEmail:
 
 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 5 of 63 SYNOPSIS  
Title of study: A Phase I, Open -label, Randomized, Parallel -arm, Single -dose Study to 
Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered 
Subcutaneously in Healthy Japanese and Caucasian Subjects  
Objectives:  
The primary objective of the study is:  
• to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneou s (SC) 
administration in healthy Japanese and Caucasian subjects. 
The secondary objectives of the study are:  
• to evaluate the safety and tolerability of AMG 133 after single SC administration in 
healthy Japanese and Caucasian subjects.  
• to evaluate the incidence of anti -AMG 133 antibodies in healthy Japanese and 
Caucasian subjects.  
Study design:  
This will be a Phase I, single- center, open -label, randomized, parallel- arm study to investigate 
the PK, safety, and tolerability of a single SC dose of AMG 133 in 3 groups of healthy 
Jap
anese subjects and 2 groups of healthy Caucasian subjects. Potential subjects will be 
screened to assess their eligibility to enter the study within 28 days prior to dose administration. Eligible subjects will be admitted into th e clinical research unit (CRU) for 
Check -in on Day -1 and be confined to the CRU until clinic discharge on Day 8. On Day 1, 21 
Japanese subjects will be randomly assigned in a 1:1:1 ratio to Group 1, 2, or 3, and 14 Caucasian subjects will be randomly assi gned in a 1:1 ratio to either Group 4 or 5. Each 
subject will participate in 1 treatment group only.  
Number of subjects:  
Approximately 35 subjects will be enrolled in total, with 7 subjects in each of the 5 groups.  
Diagnosis and main criteria for inclusi on: 
Healthy Japanese and Caucasian male or female subjects, 18 to  65 years of age (inclusive), and 
body mass index of 18 to 30  kg/m2. 
Investigational products, dose, and mode of administration:  
Investigational Medicinal Product:  mg/mL solution AMG 133  adm inistered via  
subcutaneous
 injection .  
On Day 1, AMG 133 will be administered as a SC dose to the following groups: 
• Group 
1: mg (Japanese subjects) 
• Group 2: mg (J
apanese subjects) 
• Group 3: mg (J
apanese subjects) 
• Group 4: mg (Cauc
asian subjects)  
• Group 5: mg (Caucasian subjects)  
Duration of subject participation in the study:  
Planned Screening duration: approximately 4 weeks. 
Planned study duration (Screening to End of Study visit): approximately 21 weeks.  

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 6 of 63 Primary endpoints:  
The primary endpoints for this study are AMG 133 PK parameters: maximum observed plasma 
concentration (C max), area under the plasma concentration -time curve (AUC) from time zero to 
time of last quantifiable concentration (AUC last), and area under the plasma concentration -time 
curve from time zero to infinity (AUC inf).  
Secondary endpoints:  
Secondary endpoints for this study are: adverse events, clinical laboratory tests , 12-lead 
electrocardiograms (ECGs), vital signs, and incidence of anti -AMG 133 antibody format ion. 
Statistical methods:  
The primary PK parameters will include C max, AUC last, and AUC inf for AMG 133. All other PK 
parameters will be regarded as secondary and will not be subject to inferential statistical 
analysis.  
The incidence and percentage of sub jects who develop anti-AMG 133 antibodies (binding and 
if positive, neutralizing, when available) at any time will be tabulated by treatment group. 
Tables of fatal adverse events, serious adverse events, adverse events leading to withdrawal 
from investigational product or other protocol -required therapies, and significant treatment-
emergent adverse events will also be provided. Subject -level data may be provided instead of 
tables if the subject incidence is low. Endpoints for clinical laboratory tests, ECG, and vital 
signs will be summarized.  
Additional details will be included in the Statistical Analysis Plan.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 7 of 63 TABLE OF CONTENTS  
INVESTIGATOR AGREEMENT .............................................................................................3  
STUDY IDENTIFICATION .....................................................................................................4  
SYNOPSIS  .................................................................................................................................5  
TABLE OF CONTENTS  ...........................................................................................................7  
LIST OF TABLES AND F IGURES ........................................................................................10  
LIST OF ABBREVIATION S ..................................................................................................11  
1. INTRODUCTION  ...........................................................................................................13  
1.1. Background ............................................................................................................13  
1.1.1.  Investigational Drug Product: AMG 133 .....................................................13  
1.1.2.  Pharmacology  ..............................................................................................13  
1.2. Nonclinical Pharmacokinetics  ...............................................................................13  
1.3. Nonclinical Toxicology .........................................................................................14  
1.4. Preliminary Clinical Data  ......................................................................................14  
1.5. Study Rationale  ......................................................................................................14  
1.6. Benefit -risk Assessment .........................................................................................15  
1.6.1.  Therapeutic Context  .....................................................................................15  
1.6.1.1.  Key Benefits .......................................................................................15  
1.6.1.2.  Key Potential Risks  ............................................................................15  
1.6.1.2.1.  Gastrointestinal Tolerability Issues ..........................................15  
1.6.1.2.2.  Hypersensitivity Reactions  ......................................................15  
1.6.1.2.3.  Injection Site Reactions  ...........................................................16  
1.6.1.2.4.  Immunogenicity  .......................................................................16  
2. OBJECTIVES AND ENDPO INTS  .................................................................................16  
2.1. Objectives  ..............................................................................................................16  
2.2. Endpoints ...............................................................................................................17  
2.2.1.  Primary Endpoints .......................................................................................17  
2.2.2.  Secondary Endpoints ...................................................................................17  
3. INVESTIGATIONAL PLAN  ..........................................................................................17  
3.1. Overall Study Design and Plan  ..............................................................................17  
3.2. Discussion of Study Design ...................................................................................18  
3.3. Selection of Doses in the Study .............................................................................18  
4. SELECTION OF STUDY POPULATION  .....................................................................19  
4.1. Inclusion Criteria  ...................................................................................................19  
4.2. Exclu sion Criteria  ..................................................................................................19  
4.3. Screen Failures and Rescreening  ...........................................................................22  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 8 of 63 4.4. Subject Number and Identification ........................................................................22  
4.5. Subject Withdrawal and Replacement  ...................................................................22  
4.6. Study Termination  .................................................................................................23  
5. STUDY TREATMENTS  .................................................................................................23  
5.1. Investigational Product ..........................................................................................23  
5.2. Investigational Product Administration  .................................................................24  
5.3. Treatment of Overdose  ..........................................................................................25  
5.3.1.  Medical Devices ...........................................................................................25  
5.3.2.  Product Complaints ......................................................................................25  
5.4. Randomization .......................................................................................................25  
5.5. Blinding..................................................................................................................25  
5.6. Treatment Compliance  ...........................................................................................25  
5.7. Drug Accountability...............................................................................................26  
6. CONCOMITANT THERAPIES AND OTHER RESTRICTIONS  ................................26  
6.1. Concomitant Therapies ..........................................................................................26  
6.2. Diet .........................................................................................................................26  
6.3. Smoking .................................................................................................................27  
6.4. Exercise ..................................................................................................................27  
6.5. Blood Donation ......................................................................................................27  
7. STUDY ASSESSMENTS AND PROCEDURE S ...........................................................27  
7.1. Pharmacokinetic Assessments  ...............................................................................28  
7.1.1.  Pharmacokinetic Blood Sample Collection and Processing ........................28  
7.1.2.  Analytical Methodology ..............................................................................28  
7.2. Antidrug Antibody Assessments............................................................................28  
7.3. Safety and Tolerability Assessments  .....................................................................29  
7.3.1.  Adverse Events and Serious Adverse Events: Time Period and Frequency 
for Collecting and Reporting Safety Event Information ..............................29  
7.3.2.  Clinical Laboratory Evaluations ..................................................................31  
7.3.3.  Vital Signs  ....................................................................................................32  
7.3.4.  12-lead Electrocardiogram ...........................................................................32  
7.3.5.  Physical Examination ...................................................................................32  
8. SAMPLE SIZE AND DATA ANALYSIS  ......................................................................32  
8.1. Determination of Sample Size  ...............................................................................32  
8.2. Analysis Populations ..............................................................................................33  
8.2.1.  Pharmacokinetic Population ........................................................................33  
8.2.2.  Safety Population .........................................................................................33  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 9 of 63 8.3. Pharmacokinetic Analyses  .....................................................................................33  
8.4. Antidrug Antibody Analysis ..................................................................................33  
8.5. Safety Analysis  ......................................................................................................33  
8.6. Interim Analysis  .....................................................................................................33  
9. REFERENCES  ................................................................................................................34  
10. APPENDICES  .................................................................................................................35  
Appendix 1: Safety  Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting of Adverse Events, Serious Adverse Events ...............36  
Appendix 2: Clinical Laboratory Evaluations ...................................................................44  
Appendix 3: Total Blood Volume......................................................................................46  
Appendix 4: Contraception Requirements .........................................................................47  
Appendix 5: Collec tion of Pregnancy and Lactation Information  .....................................49  
Appendix 6: Regulatory, Ethical, and Study Oversight Considerations ............................53  
Appendix 7: Hepatotoxicity: Suggested Actions and Follow- up Assessments .................58  
Appendix 8: Schedule of Assessments ..............................................................................61  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 10 of 63 LIST OF TABLES AND FIGURES  
Table 1:  Investigational Product ..............................................................................24  
  
Figure  1:  Study Design  ..............................................................................................18  
Figure 2:  Sample Serious Adverse Event Report Form ............................................41  
Figure 3:  Pregnancy Notification Form .....................................................................51  
Figure 4:  Lactation Notification Form ......................................................................52  
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 11 of 63 LIST OF ABBREVIATIONS  
Abbreviation Definition  
ADA  antidrug antibodies  
ALT  alanine aminotransferase  
AST  asparatate aminotransferase  
AUC inf area under the plasma concentration -time curve from time zero to 
infinity  
AUC last area under the plasma concentration -time curve from time zero to time 
of last quantifiable concentration  
AV atriov entricular  
cAMP  cyclic adenosine monophosphate  
CFR  Code of Federal Regulations  
Cmax maximum observed plasma concentration  
CRU  clinical research unit  
DILI  drug-induced liver injury  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
EOS  end of study  
FIH first-in-human  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GIP glucose -dependent insulinotropic polypeptide  
GIPR  glucose -dependent insulinotropic polypeptide receptor  
GLP -1 glucagon -like peptide 1  
GLP -1R GLP -1 receptor  
HR heart rate  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for/Conference on Harmonisation  
IMP investigational medicinal product  
INR International normalized ratio  
IPIM  Investigational Product Instruction Manual  
IRB Institutional Review Board  
IV intravenous  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 12 of 63 mAb  monoclonal antibody  
PK pharmacokinetic(s)  
QTcF  QT interval corrected for heart rate using Fridericia’s method  
SC subcutaneous  
TBL  total bilirubin  
ULN  upper  limit of normal  
 
  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 13 of 63 1. INTRODUCTION 
Refer to the Investigator’s Brochure (IB)1 for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event profile of the 
investigational medicinal product (IMP). 
1.1. Background 
Obesity (defined as body mass index of ≥ 30 kg/m2)2 is a major risk factor for type 2 diabetes 
mellitus and cardiovascular disease. Glucose -dependent insulinotropic polypeptide (GIP) and 
glucagon -like peptide 1 (GLP- 1) are gut -derived incretin hormones, known for their ability to 
augment glucose- stimulated  insulin secretion through the GIP receptor (GIPR) and GLP-1 
receptor (GLP -1R), respectively. In addition, GLP-1 is also known to promote satiety3, while 
GIP has been shown to promote adiposity.4,5  
1.1.1. Investigational Drug Product: AMG 133 
AMG 133 is engineered by conjugation of a human monoclonal antihuman GIPR antagonist 
antibody (mAb) with 2 identical GLP -1 analog peptides, and therefore, exhibits both GIPR 
antagonism and GLP- 1R agonism activities.  
1.1.2. Pharmacology  
In human embryonic kidney 293T cells stably expressing human GIPR, AMG 133 binds with a dissociation constant (Kd) of 37 pM and inhibits GIP-induced accumulation of cyclic adenosine monophosphate (cAMP), with a half- maximal inhibitory concentration (IC
50) of 42.4 nM. In 
addition, using a GLP-1 radioligand competition binding assay, AMG 133 binds to human GLP -1R with an IC
50 of 55.2 nM. In Chinese hamster ovary K1 cells stably expressing human 
GLP -1R, AMG 133 binds to the GLP- 1R and activates GLP -1 increasing cAMP levels with half -
maximal effective con centration (EC50) of 24.4 pM. 
In preclinical studies in obese cynomolgus monkeys, AMG 133 administration resulted in an approximate weight reduction of 17%, compared with vehicle, with concomitant decreases in food intake, insulin, and triglyceride levels. 
1.2. Nonclinical Pharmacokinetics  
AMG 133 pharmacokinetics (PK) is defined based on intact AMG 133 molecule (anti- GIPR 
mAb with at least 1 GLP -1 analog peptide) or total AMG 133 (anti-GIPR mAb with or without 
GLP -1 analog peptide).  
The PK of AMG 133 has been evaluated in single-dose studies in the mouse and cynomolgus 
monkeys w
ith a dose of 5 mg/kg intravenous (IV) and 3 mg/kg subcutaneous (SC), respectively.  
Exposure
 of intact and total AMG 133 were also evaluated in the mouse and cynomolgus 
monkey in repeat-dose toxicology studies including a 4 -week exploratory study and a pivotal 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 14 of 63 Good Laboratory Practices -compliant 13- week SC repeat -dose. The doses evaluated in the 13-
week GLP toxicology studies in mice ranged from 25 to 150 mg/kg and in cynomolgus monkeys 
from 20 to 120 mg
/kg. In both the total and intact forms, AMG 133 exhibited linear 
pharmacokinetics in both mice and cynomolgus monkeys, regardless of the regimens (single or 
repeat) at all dose levels evaluated. Terminal half -life estimates in the obese c ynomolgus 
monkeys ranged from 231 to 284 hours for total AMG 133, and from 189 to 222 hours for intact AMG 133. Some loss of the GLP-1 moiety of AMG 133 was observed in repeat-dose GLP mouse and cynomolgus monkey toxicology studies, but significant exposure of intact AMG 133 was maintained throughout the study.
1  
1.3. Nonclinical Toxicology 
The cynomolgus monkey and the mouse were selected as the nonclinical toxicology species. In in vitro studies, AMG 133 binds with similar affinity to human, cynomolgus monkey, and mouse GIPR. Whereas AMG 133 functionally inhibits GIP signaling through human and cynomolgus monkey GIPR in vitro with equivalent potency, it has more than 20-fold lower potency for inhibition of GIP signaling through mouse GIPR. AMG 133 shows equivalent potency for human, cynomolgus monkey, and mouse GLP-1R. Despite the lower potency of AMG 133 for mouse GIPR, the high exposures obtained in the repeat-dose toxicology studies in the mouse likely achieved at least partial GIPR antagonism.  
The studies conducted in the safety assessment of AMG 133 included exploratory 4- week SC 
repeat -dos
e and Good Laboratory Practice-compliant 13- week SC repeat -dose toxicology studies 
conducted in the mouse and the cynomolgus monkey. AMG 133- associated changes were 
limited to the anticipated pharmacological action of the molecule (eg, decreases in body weight, decreases in food consumption, atrophy of adipose tissue, decreased serum triglyceride in ≥ 1 studies) and minimal to mo derate changes in red blood cell parameters and/or some clinical 
chemistry parameters, which are clinically monitorable. The no -observed -adverse -effect level for 
the 13- week SC repeat -dose toxicology studies in the mouse and the cynomolgus monkey was 
the h ighest tested doses of 150 and 120 mg/kg, r
espectively. 
1.4. Preliminary Clinical Data  
As of July 2021, a total of 49 subjects received a single dose of AMG 133 or placebo across doses rangi
ng from 21 to 840 mg adminis
tered SC in the ongoing first- in-human (FIH )  single -
ascending -dose trial  and eight subjects have received repeat -doses of AMG 133  mg 
administered every 4 weeks or placebo in the ongoing multiple-dose trial.  So far, AMG 133 (in SAD and MAD cohorts) has been generally well tolerated across the d oses evaluated. No serious 
adverse events or deaths have been reported, and most adverse events reported were mild consisting of nausea, vomiting, and dyspepsia.   
1.5. Study Ration
ale 
AMG 133 has not been previously studied in healthy Japanese or healthy Caucasian subjects 
without obesity. The objective of this study is to evaluate the PK, safety, and tolerability of a 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 15 of 63 single SC dose of AMG 133 at 3 dose levels ( , and  mg) in Japanese subjects and at 
2 dose levels (  and  mg)
 in Caucasian subjects. This study will inform about any possible 
ethnic differences in PK between Japanese and Caucasian subjects.  
1.6. Benefit -risk
 Assessment  
The following benefit-risk assessment supports the conduct of this clinical study. Refer to the IB1 
for more information. 
1.6.1. Therapeutic Context  
1.6.1.1. Key Benefits  
Healthy subjects in the current study will not receive any health benefit (beyond that of an 
assessment of their medical status) from participating in the study.  
1.6.1.2. Key Potential Risks 
To limit the risk of excessive exposure to healthy subjects in the current study, subjects will be administ
ered as a single SC dose of AMG 133 at 3 dose levels ( , and  mg) in 
J
apanese subjects and at 2 dose levels (  and  mg) in Caucasian subjects (details provided 
in Section 3.3).  
1.6.1.2.1. Gast
rointestinal Tolerability Issues 
Gastrointestinal tolerability issues including nausea, vomiting, and diarrhea are common adverse reactions for molecules targeting the obesity pathways.  Gastrointestinal tolerability issues in 
humans are expected based on experience with marketed GLP -1R agonists. Subjects will be 
monitored for signs and symptoms of adverse events of nausea, vomiting, and diarrhea throughout the study.  
1.6.1.2.2. Hypersensitivity Re actions 
As with any biologic, administration of AMG 133 may result in systemic reactions including 
immune -mediated hypersensitivity. Drug hypersensitivity reactions typically occur during or 
within several hours after drug administration, but they may be delayed. Severe reactions may occur, including anaphylaxis, angioedema, and serum- like sickness. Potential anaphylactic 
reactions will be assessed by Sampson criteria. If Sampson criteria are positive, the potential anaphylactic reaction will be confirmed by measuring tryptase in blood plasma within 30 minutes of symptoms, and at any other time points as warranted and if feasible. AMG 133 will be administered by SC injection by a qualified clinical research staff member. Subjects will be monitored for signs and symptoms of hypersensitivity reactions during and after AMG 133 administration, such as fever, chills, shaking, hypotension, wheezing, itching, nausea, and/or rash.  

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 16 of 63 1.6.1.2.3. Injection Site Reactions  
Injection site reactions (eg, erythema, itching, hematoma, swelling, bruising, and pain) are 
common side effects of drugs with SC administration. These reactions can range from mild to severe (including injection site necrosis, which is an uncommon side effect). After SC administration, subjects will be monitored for injection site reactions, which may include redness, tenderness/pain, bruising, warmth, swelling, itching, and/or infection. If appropriate, photographic documentation of injection site reactions will be obtained.  
1.6.1.2.4. Immunogenicity  
As with all biologica l products, there is a potential for the development of anti-AMG 133 
antibodies. The potential effects of anti-AMG 133 antibodies on subjects who might develop 
them are not known, but reduced efficacy of AMG 133 is a possibility. Subjects will be monitored for potential effects of antidrug antibodies (ADA) that may include antibody -mediated 
adverse events, altered drug exposure, or loss of efficacy. Pharmacokinetic and immunogenicity samples from subjects in this Phase I study will be collected from study s ubjects at 
protocol-defined intervals and analyzed to monitor the development of anti-AMG 133 antibodies. Positive samples will be titrated and evaluated for neutralizing antibodies. Additional blood samples may be obtained to evaluate any ADA- mediated eff ects on safety during the 
study.  
The above benefit risk assessment supports the conduct of this clinical trial. Reference should be 
made to the IB for further data on potential side effects of AMG 133. 
2. OBJECTIVES AND ENDPOINTS  
2.1. Objectives  
The primary objec tive of the study is: 
• to evaluate the PK of AMG 133 after single SC administration in healthy Japanese and 
Caucasian subjects.  
The secondary objectives of the study are:  
• to evaluate the safety and tolerability of AMG 133  after single SC administration in 
healthy Japanese and Caucasian subjects.  
• to evaluate the incidence of anti -AMG 133 antibodies in healthy Japanese and Caucasian 
subjects.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 17 of 63 2.2. Endpoints  
2.2.1. Primary Endpoints  
The primary endpoints of the study are: 
• maximum observed plasma concentration (C max) 
• area under the plasma concentration ‑time curve from time zero to time of last 
quantifiable concentration (AUC last) 
• area under the plasma concentration ‑time curve from time zero to infinity (AUC inf). 
2.2.2. Secondary Endpoints  
The secondary endpoints of the study are: 
• adverse events  
• clinical laboratory tests  
• 12-lead electrocardiograms (ECGs)  
• vital signs  
• incidence of anti -AMG 133 antibodies. 
3. INVESTIGATIONAL PLAN  
3.1. Overall Study Design and Plan 
This will be a Phase I, single -center, open-label, randomized, parallel- arm study to investigate 
the PK, safety, and tolerability of a single SC dose of AMG 133 in 3 groups of healthy Japanese 
subjects and 2 groups of healthy Caucasian subjects.  
Approximately 35 subjects will be enrolled in total, with 7 subjects in each of the 5 groups.  Potential subjects will be screened to assess their eligibility to enter the study within 28 days 
prior to dose administration. Eligible subjects will be admitted into th e clinical research unit 
(CRU) for Check -in on Day -1 and be confined to the CRU until clinic discharge on Day 8. On 
Day 1, 21 Japanese subjects will be randomly assigned in a 1:1:1 ratio to Group 1, 2, or 3, and 14 Caucasian subjects will be randomly assi gned in a 1:1 ratio to either Group 4 or 5. Each 
subject will participate in 1 treatment group only.  
On Day 1, AMG 133 will be administered as a single SC dose to the following groups: 
• Group 1:  mg (Japanese subjects)  

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 19 of 63 preliminary PK data from this study demonstrate that intact AMG 133 a nd total AMG 133 
plasma exposures increase in a dose- proportional manner.  
The doses , and  mg are selected for evaluation in Japanese subjects and will enable 
an asses
sment of pharmacokinetic linearity within the AMG 133 dose range that is anti cipated to 
be clinically relevant. The highest dose of  mg is selected as this is the highest dose planned 
for the ongoing multiple -ascending -dose study  mg administered every 4 weeks) and is the 
highest anticipated dose to be tested in a Phase 2 study.  
4. SELECTIO
N OF STUDY POPULATION 
4.1. Inclusion Criteria  
Subjects must satisfy all of the following criteria prior to enrollment unless otherwise stated:  
1. Subject has provided informed consent before initiation of any study- specific 
activities/procedures.  
2. Japanese subjects must be first -generation Japanese (4 grandparents, biological parents, 
and subject born in Japan).  
3. Healthy male or female subjects between 18 and 65 years of age (inclusive) at the time of 
Screening.  
4. In good health, determined by no clini cally significant findings from medical history, 
physical examination, 12- lead ECG, vital signs measurements, and clinical laboratory 
evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert’s 
syndrome based on total and direct bil irubin] is not acceptable) as assessed by the 
Investigator (or designee).  
5. Body mass index between 18 and 30 kg/m2 at the time of Screening.  
6. Females of nonchildbearing potential defined as permanently sterile (ie, due to hysterectomy, bilateral salpingectom y, and/or bilateral oophorectomy) or postmenopausal 
(defined as at least 45 years of age with amenorrhea for 12 months without an alternative medical cause and follicle- stimulating hormone [FSH] level ≥ 40 mIU/mL).  
4.2. Exclusion Criteria  
Subjects will be excluded from the study if they satisfy any of the following criteria prior to 
enrollment unless otherwise stated: 
1. History or evidence, at Screening or Check -in, of clinically significant disorder, 
condition, or disease not otherwise excluded that, in the opinion of the Investigator (or 
designee), would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion. 

Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 20 of 63 2. History or current signs or symptoms of cardiovascular disease, including, but not limited 
to, myocardial infarctio n, congenital heart disease, valvular heart disease, coronary 
revascularization, or angina. 
3. History or evidence of clinically significant arrhythmia at Screening, including any clinically significant findings on the ECG taken at Check-in. 
4. A QT interval corrected for heart rate (HR) based on the Fridericia method (QTcF) interval >450 ms in male subjects or >470 msec in female subjects or history/evidence of long QT syndrome (confirmed by calculating the mean of the original value and 2 repeats) at Screening or Check -in. 
5. PR interval >200 ms, second-degree atrioventricular (AV) block, or third- degree AV 
block at Screening or Check -in. 
6. Systolic blood pressure >140 mmHg or < 90 mmHg, or diastolic blood pressure >90 mmHg, or HR >100 bpm at Screening or Check- in. 
7. History of hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor. 
8. Poor peripheral venous access. 
9. Estimated glomerular filtration ra te less than ≤ 80 mL/min/1.73 m
2 as calculated by the 
Modification of Diet in Renal Disease equation at Screening or Check -in. 
10. Alanine aminotransferase or aspartate aminotransferase > the upper limit of normal at Screening or Check -in.  
11. Positive hepatitis B or hepatitis C panel and/or positive human immunodeficiency virus test at Screening. Subjects whose results are compatible with prior immunity (vaccination or prior infection) may be included. 
12. Use of any over -the-counter or prescription medications within 30 days or 5 half- lives 
(whichever is longer) before Check-in. 
a. Acetaminophen (paracetamol;  up to 2 g per day) for analgesia will be allowed. 
b. Hormone replacement therapy (eg, estrogen) will be allowed.  
13. All herbal medicines (eg, St. John’s wort), vitamins, and supplements consumed by the subject within the 30 days prior to enrollment, unless deemed acceptable by the Investigator (or designee) and in consultation with the Sponsor. 
14. Consumption of foods and beverages containing poppy seeds within 7 days prior to Check -in. 
15. History of alcoholism or drug/chemical abuse within 1 year prior to Check -in. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 21 of 63 16. Alcohol consumption from 48 hours prior to Check-in and prior to each clinic visit and 
agrees to limit alcohol intake to a maximum of 1 unit/day on all other days, while not in 
the CRU, from Screening through the EOS visit. 
17. Regular alcohol consumption of >14 units per week for males and >7 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine.  
18. Use of tobacco - or nicotine-containing products within 6 months prior to Check-in. 
19. Unwilling to maintain normal level of physical activity from 7 days before Check -in until 
the EOS visit (ie, will not begin a new exercise program nor participate in any unusually strenuous physical exertion).  
20. Positive test for illicit drugs, cotinine (tobacco or nicotine use), and/or alcohol use at Screening or Check -in. 
21. Consumption of caffeine-containing foods and beverages within 48 hours prior to Check -in. 
22. Female subjects with a positive pregnancy test at Screening or Check -in.  
23. Female subjects lactating/breastfeeding or who plans to breastfeed during the study through 90 days after the EOS visit. 
24. Unwilling to adhere to contraceptive requirements through 90 days after the EOS visit (see Appendix 4).  
25. Unwilling to abstain from sperm donation through 90 days after the EOS visit (see Appendix 4).  
26. Male subjects with a female partner of childbearing potential and not willing to inform his partner of his participation in this clinical study.  
27. Male subjects with a pregnant partner or partner planning to becom e pregnant who are 
unwilling to practice abstinence (refrain from heterosexual intercourse) or use contraception while the subject is on study through 90 days after the EOS visit. 
28. Subject has received a dose of an investigational drug within the past 90 da ys or 
5 half -lives, whichever is longer, prior to Check- in. 
29. Have previously completed or withdrawn from this study or any other study investigating AMG 133 or have previously received the investigational product.  
30. Donation of blood from 3 months prior to C heck -in, plasma from 2 weeks prior to 
Check -in, or platelets from 6 weeks prior to Check-in. 
31. Unwilling to abide with study restrictions.  
32. Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 22 of 63 4.3. Screen Failures a nd Rescreening  
Screen failures are defined as subjects who consent to participate in the clinical study, but are not 
subsequently enrolled in the study because they do not meet eligibility requirements. A minimal set of screen failure information will be c ollected that includes demography, screen failure 
details, eligibility criteria, medical history, prior therapies, and any serious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened o nly once.  
4.4. Subject Number and Identification  
Subjects will have a unique identification number used at Screening. Subjects will be assigned a subject number prior to the first dosing occasion. Assignment of subject numbers will be in ascending order and no numbers will be omitted (eg,  Subjects 0101, 0102, 0103). Replacement 
subjects will be assigned a subject number corresponding to the number of the subject he/she is replacing plus 1000 (eg, Subject  1101 replaces Subject 0101). 
Subjects will be identified by subject number only on all study documentation. A list identifying the subjects by subject number will be kept in the Site Master File.  
4.5. Subject Withdrawal and Replacement  
A subject is free to withdraw from the study at any time. In addition, a subject will be withdrawn from dosing if any of the following criteria are met: 
• change in compliance with any inclusion/exclusion criterion that is clinically relevant and affects subject safety as determined by the Investigator (or designee)  
• noncompliance with the study restrictions that might affect subject safety or study 
assessments/objectives, as considered applicable by the Investigator (or designee) 
• any clinically relevant sign or symptom that, in the opinion of the Investigator (or designee), warrants subjec t withdrawal.  
If a subject is withdrawn from dosing, the Sponsor (or designee) will be notified and the date and reason(s) for the withdrawal will be documented in the subject’s electronic Case Report Form (eCRF). If a subject is withdrawn, efforts will be made to perform all EOS assessments, if 
possible ( Appendix 8). Other procedures may be performed at the Investigator’s (or designee’s) 
and/or Sponsor’s discretion. If the subject is in-house, these procedures should be performed before the subject is discharged from the clinic. The Investigator (or designee) may also request that the subject return for an additional follow-up visit. All withdrawn subjects will be followed until resolution of all their adverse events, serious adverse events, or until the unresolved adverse events, serious adverse events are judged by the Investigator (or designee) to have stabilized. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 23 of 63 Subjects who are withdrawn for reasons not related to study drug may be replaced following 
discussion between the Investigator and the Sponsor. Subjects withdrawn as a result of adverse events/serious adverse events thought to be related to the study drug will generally not be replaced.  
4.6. Study Te rmination 
The Sponsor may stop the study or study site participation in the study for medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, regulations, and Good Clinical Practice. Both the Sponsor and the Investiga tor reserve the right to terminate the 
Investigator's participation in the study according to the Clinical Trial Agreement. The Investigator is to notify the Institutional Review Board (IRB) in writing of the study's completion or early termination and send a copy of the notification to the Sponsor. The Sponsor reserves the unilateral right, at its sole discretion, to determine whether to supply investigational product and by what mechanism, after termination of the study.  
In addition, the study may be terminated by the Sponsor at any time and for any reason. If the Sponsor decides to terminate the study, they will inform the Investigator as soon as possible.  
5. STUDY TREATMENTS  
Study treatment is defined as any investigational product, non-investigational product, placebo, 
or medical device intended to be administered to a study subject according to the study protocol. 
Note that in several countries, investigational product and non-investigational product are 
referred to as IMP and non- IMP, respectively.  
5.1. Inves tigational Product 
The IMP will be supplied by the Sponsor. The Investigational Product Instruction Manual (IPIM), a document external to this protocol, contains detailed information regarding the storage, preparation, destruction, and administration of the IMP shown in Table 1. 
All supplies of investigational product, both bulk and subject-specific, will be stored in 
accordance with the manufacturer’s instru ctions or pharmacy instructions. Until dispensed to the 
subjects, the investigational and non- investigational products will be stored at the study site in a 
location that is locked with restricted access.  
For preparation instructions, refer to the IPIM. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 25 of 63 5.3. Treatment of Overdose 
The effects of overdose of AMG 133 are not known. In case of overdose, consultation with the 
medical monitor is recommended for prompt reporting of clinically apparent or laboratory adverse events possibly related to overdose, and to discuss further management of the subject.  
5.3.1. Medical Devices  
No investigational medical device(s) will be used in this study.  
Other non-investigational medical devices may be used in the conduct of this study as part of standard care. Non -Amgen non- investigational medical devices (eg, syringes, sterile needles) 
that are commercially available are not usually provided or reimbursed by the Sponsor (except, for example, if required by local regulation). The Investigator will be responsible for obtaining supplies of these devices.  
5.3.2. Product Complaints  
A product complai nt is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a 
drug(s) or device(s) after it is released for distribution to market or clinic by either the Sponsor or 
by distributors and partners for whom the Sponsor manufactures the material. This includes any 
investigational product (AMG 133) provisioned and/or repackaged/modified by the Sponsor . 
Any product complaint(s) associated with an investigational product (AMG 133) supplied by the Sponsor are to be reported according to the instructions provided in the Amgen IPIM. 
5.4. Randomization 
This is a randomized, parallel-arm study. Japanese subjects will be randomized (1:1:1) to 1 of the 
3 treat ment groups, and Caucasian subjects will be randomized (1:1) to 1 of the 2 treatment 
groups. R
andomization scheme will be provided by a biostatistician.  
5.5. Blinding  
T
his is an open- label study.  
5.6. Treatment Compliance  
The following measures will be employed to ensure treatment compliance:  
• All doses will be administered under the supervision of the Investigator  or designee . 
• At each dosing occasion, a predose and postdose inventory of AMG 133 will be performed.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 26 of 63 5.7. Drug Accountability  
The Investigator (or designee) will maintain an accurate record of the receipt of AMG 133 
received. In addition, an accurate drug disposition record will be kept, specifying the amount dispensed to each subject and the date of dispensing. This drug accountability record will be available for inspection at any time. At the completion of the study, the original drug accountability record will be available for review by the Sponsor upon request. 
For each batch of unit doses, the empty used unit dose containers will be discarded upon 
satisfactory completion of the compliance and accountability procedures. Any unused assembled unit doses will be retained until completion of the study. 
At the completion of the study, all unused AMG 133 will be returned to the Sponsor, retained at 
the study site,  or disposed of by the study site, per the Sponsor’s written instructions. 
6.CONCOMITANT THERAPIES AND OTHER RESTRICTIONS
6.1. Concomitant Therapies  
Subjects will refrain from use of any prescription or nonprescription medications/products during the study until the EOS visit, unless the Investigator (or designee) and/or Sponsor have given their prior consent.  
Acetaminophen  (paracetamol; 2 g/day) or hormone replacement therapy are acceptable 
concomitant medications. The administration of any other concomitant medications during the study is prohibited without prior approval of the Investigator (or designee), unless its use is deemed necessary for treatment of an adverse event/serious adverse event. Any medication taken by a subject during the course of the study and the reason for its use will be documented in the source data.  
6.2. Diet 
Subjects will be fasted overnight (at least 8  hours) before collection of blood samples for clinical 
laboratory evaluations. While confined at the study site, subjects will receive a standardized diet at scheduled times that do not conflict with other study -related activities.  
Refer to Section 5 and  Table 1 for diet requirements/restrictions on applicable days of study 
treatment and/or PK assessments.  
Foods and beverages containing poppy seeds will not be allowed from 7 days prior to Check -in 
until EOS visit.   
Caffeine -containing foods and beverages will not be allowed from 48 hours before each study 
visit through the EOS visit.   
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 27 of 63 Consumption of alcohol will not be permitted from 48 hours prior to each clinic visit, and 
alcohol intake w ill be limited to a maximum of 1 unit/day on all other days, while not in the 
CRU, from Screening through the EOS visit.  
6.3. Smoking  
Subjects will not be permitted to use tobacco - or nicotine-containing products within 6 months 
prior to Check- in until the EOS  visit.  
6.4. Exercise  
Subjects are required to refrain from strenuous exercise from 7  days before Check- in until the 
EOS visit. Subjects will otherwise maintain their normal level of physical activity during this time (ie, will not begin a new exercise program nor participate in any unusually strenuous physical exertion).  
6.5. Blood Donation 
Subjects are required to refrain from donation of blood from 3 months  prior to Check-in, plasma 
from 2 weeks prior to Check-in, and platelets from 6 weeks prior to Check-in unti l 3 months  
after the EOS visit.  
7. STUDY ASSESSMENTS AND PROCEDURES  
Every effort will be made to schedule and perform the procedures as closely as possible to the 
nominal time, giving considerations to appropriate posture conditions, practical restrictions, and the other procedures to be performed at the same timepoint. 
The highest priority procedures will be performed closest to the nominal time. The order of 
priority for scheduling procedures around a timepoint is (in descending order of priority): 
• dosing 
• safety assessments (ECGs will be scheduled before vital signs measurements)  
• PK blood samples 
• antidrug antibody samples 
• any other procedures.  
Where activities at a given timepoint coincide, consideration must be given to ensure that the following order of activities is maintained: ECGs, vital signs, and clinical laboratory 
assessments.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 28 of 63 7.1. Pharmacokinetic Assessments  
7.1.1. Pharmacokinetic Blood Sample Collection and Processing  
Blood samples will be collected by venipuncture or cannulation at the times indicated in th e 
Schedule of Assessments in Appendix 8. Procedures for collection, processing, and shipping of 
PK blood samples will be detailed in a separate document.  
Any blood sample collected according to the Schedule of Assessments ( Appendix 8) can be 
analyzed for any of the tests outlined in the protocol and for any tests necessary to minimize 
risks to study subjects. This includes testing to ensure analytical methods produce reliable and valid data throughout the course of the study. This can also include, but is not limited to, investigation of unexpected results, incurred sample reanalysis, and analyses for method transfer and comparabili ty.  
7.1.2. Analytical Methodology 
Plasma  concentrations of AMG 133 will be determined using validated analytical procedures. 
Specifics of the analytical method will be provided in a separate document (ie, Statistical Analysis Plan).  
7.2. Antidrug Antibody Assessment s 
Serum  samples for antibody testing are to be collected as outlined in the Schedule of 
Assessments in Appendix 8. 
Bioanalytical testing for anti-AMG 133 antibodies will be conducted on these samples using a 
fully validated, electrochemiluminescence- based immunoassay. All samples that test positive for 
ADA will be titered and evaluated for neutralizing antibodies against human GLP-1 using a cell-based assay . All neutralizing antibody positive subjects and subjects who tested positive for 
binding ADAs at the final scheduled study visit, defined as the EOS visit, and have clinical sequelae that are considered potentially related to an anti -AMG 133 antibody response will be 
asked to return for additional follow-up testing until the ADA responses have returned to (1) baseline, (2) a low titer, or (3) the subject has been followed for a period of at least 1 year (±4 weeks) post-administration of AMG 133. All follow-up results, both positive and negative will be communicated to the sites. More frequent testing or testing for a longer period of time may be requested in the event of safety -related concerns. Follow -up testing will not be required where it 
is establishe d that the subject did not receive AMG 133. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 29 of 63 7.3. Safety and Tolerability Assessments  
7.3.1. Adverse Events and Serious Adverse Events: Time Period and Frequency for 
Collecting and Reporting Safety Event Information 
Adverse event definitions, assignment of severity and causality, and procedures for reporting adverse events and serious adverse events are detailed in Appendix 1. 
The condition of each subject will be monitored from the time of signing the ICF to EOS visit. 
Subjects will be observed for any signs or symptoms and asked about their condition by open questioning, such as “How have you been feeling since you were last asked?”, at least once each day while res ident at the study site and at each study visit. Subjects will also be encouraged to 
spontaneously report adverse events and serious adverse events occurring at any other time during the study. 
Adverse Events  
The adverse event grading scale to be used in this study is described in Appendix 1.  
The Investigator is responsible for ensuring that all non-serious adverse events observed by the Investigator or reported by the subject (whether reported by the subject voluntarily or upon questioning, or noted on physical examination) from enrollment through the EOS visit are recorded/reported using the appropriate eCRF. 
Serious Adverse Events  
The Investigator is responsible for ensuring that all serious adverse events observed by the Investigator or reported by the subject that occur after signing of the ICF through 30 days after the last dose of study treatment or the EOS visit (whichever is later) are reported using the appropriate eCRF and reported on the paper-based Serious Adverse Event Report Form (described in  Appendix 1).  
All serious adverse events will b e collected, recorded, and reported to the Sponsor within 
24 hours of the Investigator’s knowledge of the event. The Investigator will submit any updated serious adverse event data to the Sponsor within 24 hours of it being available. 
Serious Adverse Events After the Protocol -required Reporting Period  
There is no requirement to monitor study subjects for serious adverse events following the protocol-required reporting period or after EOS. However, these serious adverse events should be reported to Amgen (r egardless of causality) if the Investigator becomes aware of them. Per 
local requirements in some countries, Investigators are required to report serious adverse events that they become aware of after EOS. If serious adverse events are reported, the Invest igator is to 
report them to the Sponsor within 24 hours following the Investigator’s knowledge/awareness of the event using the paper-based Serious Adverse Event Report Form.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 30 of 63 Serious adverse events reported outside of the protocol-required reporting period will be 
captured within the Sponsor’s safety database as clinical trial cases and handled accordingly based on relationship to investigational product.  
Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting adverse events and/or serious adverse events. Open- ended and non-leading verbal questioning of the subject is the preferred method to 
inquire about adverse event occurrence. 
Follow- up of Adverse Events and Serious Adverse Events  
After t he initial adverse event/serious adverse event report, the Investigator is required to 
proactively follow each subject at subsequent visits/contacts. All adverse events and serious adverse events will be followed, where possible, until resolution, stabilization, until the event is otherwise explained, or the subject is lost to follow-up. This will be completed at the Investigator’s (or designee’s) discretion. 
All new information for previously reported serious adverse events must be sent to Amgen 
within 24 hours following knowledge of the new information. If specifically requested, the Investigator may need to provide additional follow-up information, such as discharge summaries, medical records, or extracts from the medical records. Information provided about the serious adverse event must be consistent with that recorded on the eCRF. 
Regulatory Reporting Requirements for Serious Adverse Events  
If subject is permanently withdrawn from protocol- required therapies because of a serious 
adverse event, this information must be submitted to the Sponsor. 
Prompt notification by the Investigator to the Sponsor of serious adverse events is essential so 
that legal obligations and ethical responsibilities towards the safety of subjects and the safety of a study treatment under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study treatment under clinical investigation. The 
Sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRBs/IECs, and Investigators. 
Individual safety reports must be prepared for suspected unexpected serious adverse reactions 
according to local regulatory requirements and sponsor policy and forwarded to Investigators as necessary.  
An Investigator who receives an individual safety report describing a serious adverse event or other specific safety information (eg, summary or listing of serious adverse events) from t he 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 31 of 63 Sponsor will file it along with the IB and will notify the IRB, if appropriate according to local 
requirements.  
Safety Monitoring Plan 
Subject safety will be routinely monitored as defined in the Sponsor’s safety surveillance and signal management proce sses. 
Pregnancy and Lactation 
Details of all pregnancies and/or lactation in female subjects and pregnancies in female partners of male subjects will be collected.  
If a pregnancy is reported, the Investigator is to inform Amgen within 24 hours of learning of the pregnancy and/or lactation and is to follow the procedures outlined in Appendix 5. Amgen Global Patient Safety will follow up with the Investigator regarding additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding p regnancy and lactation are provided in Appendix 5. 
7.3.2. Clinical Laboratory Evaluations 
Blood and urine samples will be collected for clinical laboratory evaluations (including clinical chemistry, hematology, urinalysis, and serology) at the times indicated in the Schedule of Assessments in Appendix 8. Clinical laboratory evaluations are listed in  Appendix 2. 
The Investigator is responsible for reviewing laboratory test results and recording any clinically relevant changes occurring during the study in CRF/eCRF. The Investigator must determine whether an abnormal value in an individual study subject represents a clinically significant change from the subject’s baseline values. In general, abnormal laboratory findings without clinical significance (based on the Investigator’s judgment) are not to be recorded as adverse events. However, laboratory value changes that require treatment or adjustment in current therapy are considered adverse events. Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded as the adverse event.  
Subjects will be asked to provide urine samples for drugs of abuse screen and cotinine test, and will undergo an alcohol breath or urine test at the times indicated  in the Schedule of Assessments 
in Appendix 8. For all female subjects, a pregnancy test and FSH screen for postmenopausal women will be performed at the times indicated in the Schedule of Assessments in Appendix 8.  
An Investigator (or designee) will perform a clinical assessment of all clinical laboratory data.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 32 of 63 7.3.3. Vital Signs  
Supine blood pressure, supine heart rate, respiratory rate, and oral body temperature will be 
assessed at the times indicated in the Schedule of Assessments in Appendix 8. Vital signs may also be performed at other times if judged to be clinically appropriate or if the ongoing review of the data suggests a more detailed assessment of vital signs is required.  
All measurements will be performed singly and repeated once if outside the relevant clinical reference range.  
Subjects must be supine for at least 5 minutes before blood pressure and heart rate measurements. When vital signs are scheduled at the same time as blood draws, the blood draws will be obtained at the scheduled timepoint, and the vitals will be obtained as close to the scheduled blood draw as possible, but prior to the blood draw. 
7.3.4. 12-lead Electrocardiogram  
Resting 12- lead ECGs will be recorded after the subject has been supine and at rest for at least 
5 minutes at the times indicated in the Schedule of Assessments in Appendix 8. Single 12- lead 
ECGs will be repeated tw ice, and an average taken of the 3 readings, if either of the following 
criteria apply:  
• QTcF is >500  ms 
• QTcF change from the baseline (predose) is >60  ms. 
Additional 12- lead ECGs may be performed at other times if judged to be clinically appropriate 
or if the ongoing review of the data suggests a more detailed assessment of ECGs is required. 
The Investigator (or designee) will perform a clinical assessment of each 12 -lead ECG.  
7.3.5. Physical Examination 
A full physical examination or symptom- directed physical examination will be performed at the 
timepoints specified in the Schedule of Assessments in Appendix 8.  
8. SAMPLE SIZE AND DATA ANALYSIS  
8.1. Determination of Sampl e Size 
The sample size for this study is based practical considerations. No statistical hypotheses will be 
tested. Approximately 35 subjects will be enrolled across 5 groups (7 subjects per group). The study design and sample size per dose group for this s tudy is considered adequate for evaluation 
of the study objectives. 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 33 of 63 8.2. Analysis Populations 
8.2.1. Pharmacokinetic Population  
The PK population will include all subjects who received at least 1 dose of AMG 133 and have 
evaluable PK data.  
8.2.2. Safety Population 
The safety population will include all subjects who received at least 1 dose of AMG 133. 
8.3. Pharmacokinetic Analyses  
Plasma  AMG 133 concentrations will be determined using a validated assay. Individual plasma 
concentration -time plots for AMG 133 will be presented for each subject as well as mean 
concentration -time plots for each dose group. Pharmacokinetics parameters of AMG 133 will be 
calculated using standard noncompartmental methods.  
The primary PK parameters will include C max, AUC last, and AUC inf for AMG 133. All other PK 
parameters will be regarded as secondary and will not be subject to inferential statistical analysis.  
Additional parameters may be calculated. Specific details will be presented in the Statistical 
Analysis Plan for this study.  
8.4. Antidrug Antibody Analysis 
The incidence and percentage of subjects who develop anti-AMG 133 antibodies (binding and if positive, neutralizing, when available) at any time will be tabulated by treatment group.  
8.5. Safety Analysis 
The number and percentage of subjects report ing any adverse events will be tabulated by 
Medical Dictionary for Regulatory Activities system organ class and preferred term. Tables of 
fatal adverse events, serious adverse events, adverse events leading to withdrawal from 
investigational product or other protocol-required therapies, and significant treatment- emergent 
adverse events will also be provided. Subject- level data may be provided instead of tables if the 
subject incidence is low.  
Endpoints for clinical laboratory tests, ECG, and vital signs will be summarized.  
8.6. Interim Analysis  
No interim analyses are planned for this study.  
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 34 of 63 9.REFERENCES
1. Amgen Inc. AMG 133 – Investigator’s Brochure (Version 1.0). 01 June 2020.
2. World Health Organization. Obesity and overweight; 2018. Available from:
http://www.who.int/mediacentre/factsheets/fs311/en/.
3.Turton MD, O'shea D, Gunn I, et al. A role for glucagon-like peptide- 1 in the central
regulation of feeding. Nature. 1996;379:69-72.
4.Yip RG, B
oylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on
adipocytes. Endocrinology. 1998;139:4004-4007
5.Beck B
, Max JP. Hypersensitivity of adipose tissue to gastric inhibitory polypeptide action in
the obese Zucker rat. Cell Mol Biol. 1987;33:555-562.
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 35 of 63 10. APPENDICES  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 41 of 63 Figure 2 :  Sample Serious Adverse Event Report Form  
  

Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 42 of 63 

Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 43 of 63  

Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 44 of 63 Appendix  2: Clinical Laboratory Evaluations 
Clinical chemistry:  Hematology:  Urinalysis:  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Amylase  
Lipase  
Aspartate aminotransferase  
Bicarbonate 
Blood urea nitrogen Calcium  
Chloride  
Cholesterol  
Creatinine  
Creatinine Kinase  
Hemoglobin A1C  
High -density lipoprotein (HDL)  
Low-density lipoprotein (LDL)  
Lactate dehydrogenase (LDH)  
Direct bilirubin
a 
Gamma -glutamyl transferase  
Glucose  
Indirect bilirubina 
Inorganic phosphate  
Magnesium  
Phosphorus  
Potassium  
Sodium  
Total bilirubina 
Total creatine kinase  Total protein  
Uric acid  Hematocrit  
Hemoglobin Mean cell hemoglobin  
Mean cell hemoglobin concentration  
Mean cell volume  
Platelet count  
Red blood cell (RBC) count  
RBC distribution width  
Reticulocytes
 
White blood cell (WBC) count WBC differential:  
  Basophils  
  Eosinophils  
  Lymphocytes  
  Monocytes  
  Neutrophils  
  Segmented Neutrophils  
  Bands/Stabs  
 Bilirubin  
Blood  
Color and appearance 
Glucose  
Ketones  
Leukocyte esterase  
Nitrite  
pH 
Protein  
Specific gravity  
Urobilinogen  
Microscopic examination (if 
protein, leukocyte esterase, nitrite, or blood is positive)  
 
Serologyb: Drug screenc: Hormone panel - females only:  
Anti-hepatitis B surface antibody  
Anti-hepatitis B core antibody  
Hepatitis B surface antigen  
Hepatitis C antibody  
Human immunodeficiency (HIV -1 and HIV -2) antibodies 
and p24 antigen Including but not limited to:  
Amphetamines/methamphetamin
es 
Barbiturates  
Benzodiazepines  
Cocaine (metabolite)  
Methadone  
Phencyclidine  
Opiates  
Tetrahydrocannabinol/  
cannabinoids  
Tricyclic antidepressants  
Cotinine test  
Alcohol breath or urine test  Follicle -stimulating hormone 
(postmenopausal females only) b 
Serum pregnancy test (human 
chorionic gonadotropin)d 
Urine pregnancy testd 
Other tests : 
Hepatotoxicity only: 
International normalized ratio 
(INR)e 
Estimated glomerular filtration 
rate (eGFR)f 
 
a Direct and indirect bilirubin will be analyzed if total bilirubin is elevated.  
b Only analyzed at Screening.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 45 of 63 c Only analyzed at Screening  and Check -in. Alcohol testing is not included at Screening. Cotinine testing at Screening , Check -in, 
and all outpati ent visits.  
d Performed in serum at Screening and in urine at all other times for all females. A positive urine pregnancy test will be 
confirmed with a serum pregnancy test.  
e International normalized ratio will be tested if hepatotoxicity is suspected, per guidelines presented in Appendix 7.  
f Estimated glomerular filtration rate will be calculated by the Modification of Diet in Renal Disease equation.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 46 of 63 Appendix  3: Total Blood Volume 
The following blood volumes will be withdrawn for each subject. 
 Volume per blood 
sample (mL)  Maximum number 
of blood samples  Total amount of 
blood (mL)  
Clinical laboratory 
evaluations  7.5 8 60 
Serology 3.5 1 3.5 
Serum FSH  4 1 4 
Serum pregnancy test  4 1 4 
AMG 133 
pharmacokinetics  4 16 64 
Anti-AMG 133 antibody 4 5 20 
Total:  155.5 
If extra blood samples are required, the maximum blood volume to be withdrawn per subject will 
not exceed 500 mL.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 47 of 63 Appendix  4: Contraception Requirements  
All subjects must receive pregnancy prevention counseling and be advised of the risk to the fetus 
if they conceive a child during treatment and for 90 days after the end of study (EOS) visit. 
Additional medications given during the study may alter the contraceptive requirements. The 
Investigator must discuss these contraceptive changes with the subject.  
Definition of Women of Childbearing Potential:  premenopausal females who are anatomically 
and physiologically capable of becoming pregnant following menarche.  
Women of Nonchildbearing Potential: 
1. Surgically sterile:  females who are permanently sterile via hysterectomy, bilateral 
salpingectomy, and/or bilateral oophorectomy by reported medical history and/or medical 
records. Surgical sterilization to have occurred a minimum of 6 weeks, or at the Investigator’s discretion, prior to Screening.  
2. Postmenopausal:  females at least 45 years of age with amenorrhea for 12 months 
without an alternative medical reason with confirmatory follicle -stimulating hormone 
levels of ≥ 40 mIU/mL. The amenorrhea should not be induced by a medical condition 
such as anorexia nervosa, hypothyroid disease or polycystic ovarian disease, or by extreme exercise. It should not be due to concomitant medications that may have induced the amenorrhea such as oral contraceptives, hormones, gonadotropin-releasing hormones, anti-estrogens, or selective estrogen receptor modulators.  
Fertile male:  a male that is considered fertile after puberty.  
Infertile male:  permanently sterile male via bilateral orchiectomy.  
Contraception Requirements  
Female Subjects  
Female subjects who are of nonchildbearing potential will not be required to use contraception.  
Male Subjects:  
Male subjects (even with a history of vasecto my) with partners of childbearing potential must 
use a male barrier method of contraception (ie, male condom with spermicide) in addition to a 
second method of acceptable contraception by female partner from Check- in until 90 days after 
the EOS visit. Acce ptable methods of contraception for female partners include:  
• hormonal injection  
• combined oral contraceptive pill or progestin/progestogen-only pill  
• combined hormonal patch  
• combined hormonal vaginal ring  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 48 of 63 • surgical method (bilateral tubal ligation or reg ulatory approved method of hysteroscopic 
bilateral tubal occlusion)  
• hormonal implant  
• hormonal or non-hormonal intrauterine device  
• over-the-counter sponge with spermicide  
• cervical cap with spermicide  
• diaphragm with spermicide.  
Male subjects are requir ed to refrain from donation of sperm from Check-in until 90 days after 
the EOS visit.  
Sexual Abstinence  
Subjects who practice true abstinence, because of the subject’s lifestyle choice (ie, the subject 
should not become abstinent just for the purpose of study participation), are exempt from contraceptive requirements. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. 
For subjects who practice true abstinence, sub jects must be abstinent for at least 6 months prior 
to Screening and must agree to remain abstinent from the time of signing the ICF until 90  days 
after the EOS visit.  
Same -sex Relationships 
For subjects who are exclusively in same-sex relationships, contraceptive requirements do not 
apply. 
A subject in a same- sex relationship at the time of signing the ICF must agree to refrain from 
engaging in a heterosexual relationship from the time of signing the ICF until 90 days after the 
EOS visit.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 49 of 63 Appendix  5: Collection of Pregnancy and Lactation Information 
Collection of Pregnancy Information 
Female Subjects Who Become Pregnant  
•Investigator will collect pregnancy information on any female subject who becomes
pregnant while taking protocol-required therapies through 90 days after EOS.
•Information will be recorded on the Pregnancy Notification Form  (see
Figure  3: Pregnancy Notification Form ). The form must be submitted to Amgen Global
Patient Safety within 24 hours of learning of a subject’s pregnancy. (Note: Sites are not
required to provide any information on the Pregnancy Notification Form that violates the
country or region’s local privacy laws).
•After obtaining the female subject’s signed consent for release of pregnancy and infant
health information, the Investigator will collect pregnancy and infant health information
and complete the pregnancy questionnaire for any female s ubject who becomes pregnant
while taking protocol-required therapies through 90 days after EOS. This information
will be forwarded to Amgen Global Patient Safety. Generally, infant follow-up will be
conducted up to 12 months after the birth of the child (i f applicable).
•Any termination of pregnancy will be reported to Amgen Global Patient Safety,
regardless of fetal status (presence or absence of anomalies) or indication for procedure.
•While pregnancy itself is not considered to be an adverse event or seri ous adverse event,
any pregnancy complication or report of a congenital anomaly or developmental delay,
fetal death, or suspected adverse reactions in the neonate will be reported as an adverse
event or serious adverse event. Note that an elective terminat ion with no information on a
fetal congenital malformation or maternal complication is generally not considered an
adverse event, but still must be reported to the Sponsor as a pregnancy exposure case.
•If the outcome of the pregnancy meets a criterion for immediate classification as a serious
adverse event (eg, female subject experiences a spontaneous abortion, stillbirth, or
neonatal death or there is a fetal or neonatal congenital anomaly), the Investigator will
report the event as a serious adverse event .
•Any serious adverse event occurring as a result of a post-study pregnancy which is
considered reasonably related to the study treatment by the Investigator will be reported
to Amgen Global Patient Safety as described in  Appendix 1. While the Investigator is not
obligated to actively seek this information in former study subjects, he or she may learn
of a serious adverse event through spontaneous reporting.
•Any female subject who becomes pregnant while participating will discontinue study
treatment  (see Section 5.6 for details).
Male Subjects with Partners Who Become Pregnant  or Were Pregnant at the Time of Enrollment  
•In the event a male subject fathers a child during treatment, and for an additional 90 days
after EOS, the information will be recorded on the Pregnancy Notification Form. The
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 50 of 63 form  (see Figure 3: Pregnancy Notification Form ) must be submitted to Amgen Global 
Patient Safety within 24 hours of the site’s awareness of the pregnancy. (Note: Sites are 
not required to provide any information on the Pregnancy Notification Form that violates 
the country or region’s local privacy law s). 
• The Investigator will attempt to obtain a signed consent  for release of pregnancy and 
infant health information directly from the pregnant female partner to obtain additional 
pregnancy information. 
• After obtaining the female partner’s signed consent  for release of pregnancy and infant 
health information, the Investigator will collect pregnancy outcome and infant health 
information on the pregnant partner and her baby and complete the pregnancy 
questionnaires. This information will be forwarded to Amgen Global Patient Safety.  
• Generally, infant follow-up will be conducted up to 12 months after the birth of the child 
(if applicable).  
• Any termination of the pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or ab sence of anomalies) or indication for procedure. 
Collection of Lactation Information 
• Investigator will collect lactation information on any female subject who breastfeeds 
while taking protocol-required therapies through 90 days after EOS.  
• Information will be recorded on the Lactation Notification Form ( Figure 4 ) and submitted 
to Amgen Global Patient Safety within 24 hours of the Investigator’s knowledge of event. 
• Study treatment will be discontinued if the female subject breastfeeds during the study.  
With the female subject’s s igned consent for release of mother and infant health information, the 
Investigator will collect mother and infant health information and complete the lactation 
questionnaire on any female subject who breastfeeds while taking protocol-required therapies 
through 90 days after discontinuing protocol- required therapies.
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 51 of 63 Figure 3 :  Pregnancy Notification Form 

Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 52 of 63 Figure 4 :  Lactation Notification Form 
 
 

Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 53 of 63 Appendix  6: Regulatory, Ethical, and Study Oversight Considerations 
Regulatory and Ethical Considerations 
This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines.  
• Applicable International Conference on Harmonisation (ICH) Good Clinical Practice 
(GCP) Guidelines. 
• Applicable laws and regulations. 
The protocol, protocol amendments, Informed Consent Form (ICF), Investigator’s Brochure, and 
other relevant documents (eg, advertisements) must be submitted to an Institutional Review Board (IRB) by the Investigator and reviewed and approved by the IRB before the study is initiated.  
Any amendments to the protocol will require IRB and regulatory authority (as locally required) 
approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to  study subjects.  
The Investigator will be responsible for the following: 
• Providing written summaries of the status of the study to the IRB annually or more 
frequently in accordance with the requirements, policies, and procedures established by the IRB. 
• Notifying the IRB of serious adverse events or other significant safety findings as 
required by IRB procedures.  
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 Code of Federal Regulations (CFR), ICH guidelines, the IRB, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local regulations. 
Finances and Insurance  
Financing and insurance will be addressed in a separate agreement.  
Informed Consent  
An initial sample ICF will b e provided for the Investigator (or designee) to prepare the informed 
consent document to be used at his or her site. Updates to the sample ICF are to be communicated formally in writing from the Study Manager to the Investigator. The written ICF is to be prepared in the language(s) of the potential study participant population. 
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 54 of 63 The Investigator or his/her delegated representative will explain to the subject, or his/her legally 
authorized representative, the aims, methods, anticipated benefits, and potential hazards of the study before any protocol-specific screening procedures or any investigational product(s) is/are administered and answer all questions regarding the study.  
Subjects must be informed that their participation is voluntary. Subjects or their legally 
authorized representative (defined as an individual or other body authorized under applicable law to consent, on behalf of a prospective subject, to the subject’s participation in the clinical study) will then be required to sign a statement of in formed consent that meets the requirements of 21 
CFR 50, local regulations, ICH guidelines, and the IRB or study site.  
The medical record must include a statement that written informed consent was obtained before 
the subject was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. 
The acquisition of informed consent and the subject’s agreement or refusal of his/her notification 
of the primary care physician is to be documented in the subject’s medical records, and the ICF is to be signed and personally dated by the subject or a legally acceptable representative and by the person who conducted the informed consent discussion. Subject withdrawal of consent or discontinuation from study treatment and/or procedures must also be documented in the subject’s medical records.  
Subjects must be re-consented to the most current version of the ICF during their participation in the study.  
The original signed ICF is to be retain ed in accordance with institutional policy, and a copy of 
the ICF must be provided to the subject or the subject’s legally authorized representative.  If a potential subject is illiterate or visually impaired and does not have a legally acceptable 
represen tative, the Investigator must provide an impartial witness to read the ICF to the subject 
and must allow for questions. Thereafter, both the subject and the witness must sign the ICF to attest that informed consent was freely given and understood. (Refer to ICH GCP guideline, Section  4.8.9.) 
A subject who is rescreened is not required to sign another ICF if the rescreening occurs within 28 days from the previous ICF signature date and the same version of the ICF is in use at the time of rescreening.  
Subject  Data Prote ction 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to the Sponsor. 
Subjects will be assigned a unique identifier by the Sponsor (or designee). Any subject records or 
datasets that are tran sferred to the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021 Page 55 of 63 On the electronic Case Report Form (eCRF) demographics page, in addition to the unique 
subject identification number ( Section 4.4), include the age at time of enrollment.  
For serious adverse events reported to the Sponsor (or designee), subjects are to be identified by 
their unique subject identification number ( Section 4.4) (for faxed reports, in accordance with 
local laws and regulations) and age (in accordance with local laws and regulations).  
Documents that are not submitted to the Sponsor (eg, signed ICFs) are to be kept in confidence 
by the Investigator, except as described below.  
In compliance with ICH GCP Guidelines , it is required that the Investigator and institution 
permit authorized representatives of the company, of the regulatory agency(s), and the IRB direct 
access to review the subject’s original medical records for verification of study- related 
procedures and data. Direct access includes examining, analyzing, verifying, and reproducing 
any records and  reports that are important to the evaluation of the study. 
The Investigator is obligated to inform and obtain the consent of the subject to permit such 
individuals to have access to his/her study-related records, including personal information.  
Disclosur e 
All information provided regarding the study, as well as all information collected and/or 
documented during the course of the study, will be regarded as confidential information of the Sponsor, Amgen Inc. The Investigator (or designee) agrees not to disclose such information in any way without prior written permission from the Sponsor. The information in this document cannot be used for any purpose other than the evaluation or conduct of the clinical investigation without the prior written permission from the Sponsor. 
The Investigator must ensure that the subject’s confidentiality is maintained for documents 
submitted to Amgen.  
Subject will be assigned a unique identifier by the Sponsor (or designee). Any subject records or datasets that are transferred to  the Sponsor will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
On the CRF demographics page, in addition to the unique subject identification number 
(Section  4.4), include the age at time of enrollment.  
For serious adverse events reported to Amgen, subjects are to be identified by their unique subject identification numb er (Section 4.4), initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations). 
Documents that are not submitted to Amgen (eg, signed ICFs) are to be kept in confidence by the 
Investigator, except as described below. 
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 56 of 63 Data Quality Assurance 
The following data quality steps will be implemented: 
• All relevant subject data relating to th e study will be recorded on eCRFs unless directly 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are accurate and correct by electronically signing the eCRF.  
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the eCRF.  
• The Investigator must permit study -related monitoring, audits, IRB review, and 
regulatory agency inspections and provide direct access to source data documents.  
• The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data. Predefined agreed risks, monitoring thresholds, quality tolerance thresholds, controls, and mitigation plans will be documented in a risk management register. Additional details of quality checking to be performed on the data may be included in a Data Management Plan.  
• A Study Monitor will perform ongoing source data verification to confirm that data entered into the eCRF by authorized site personnel are accurate, complete, and verifiable from source documents; that the safety and rights of subjects are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the Investigator in accordance with 21 CFR 312.62(c), unless local regulations or institutional policies require a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor.  
Investigator Documentation Responsibilities 
All individual, subject- specific study data will also be entered into a 21 CFR Part  11-compliant 
electronic data capture (EDC) system on an eCRF in a timely fashion.  
All data generated from external sources (eg, laboratory and bioanalytical data), and transmitted 
to the Sponsor or designee electronically, will be integrated with the subject’s eCRF data in accordance with the Data Management Plan.  
An eCRF must be completed for each enrolled su bject who undergoes any screening procedures, 
according to the eCRF completion instructions. The Sponsor, or Contract Research Organization, will review the supporting source documentation against the data entered into the eCRFs to 
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 57 of 63 verify the accuracy of the electronic data. The Investigator will ensure that corrections are made 
to the eCRFs and that data queries are resolved in a timely fashion by the study staff.  
The Investigator will sign and date the eCRF via the EDC system’s electronic signature proced ure. These signatures will indicate that the Investigator reviewed and approved the data on 
the eCRF, data queries, and site notifications. 
Publications  
The policy for publication of data obtained during this study will be documented in the Clinical 
Study Agreement.  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 58 of 63 Appendix 7: Hepatotoxicity: Suggested Actions and Follow- up Assessments  
Subjects with normal hepatic function at Screening who experience aspartate aminotransferase 
(AST) or alanine aminotransferase ( ALT) elevations >3 x upper limit of normal (ULN) or 
subjects with elevated values before drug exposure who have a 2- fold increase above baseline 
values (as specified in the Guidance for Industry Drug- Induced Liver Injury: Premarketing 
Clinical Evaluation, July 2009) are to undergo clinical assessments and a period of “close 
observation” until abnormalities return to normal or to the subject’s baseline level as described 
below. 
 
Clinical Assessments and Observation  
Assessments that are to be performed during this period include:  
• Repeat AST, ALT, alkaline phosphatase, bilirubin (total and direct), and international 
normalized ratio (INR) within 24 hours  
• In cases of total bilirubin (TBL) >2 x ULN or INR >1.5, retesting of liver tests, bilirubin 
(total and direct), and INR is to be performed every 24 hours until laboratory 
abnormalities improve.  
Testing frequency of the above laboratory tests may decrease if the abnormalities stabilize.  
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL. The 
following are to be considered depending on the clinical situation: 
• Complete blood count with differential to assess for eosinophilia 
• Serum total immunoglobulin G, anti-nuclear antibody anti-smooth muscle antibody, and 
liver kidney microsomal antibody-1 to assess for autoimmune hepatitis  
• Serum acetaminophen (paracetamol) levels  
• A more detailed history of:  
o Prior and/or concurrent diseases or illness 
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, 
hypersensitivity -type reactions, fatigue, nausea, vomiting, and fever 
o Prior and/or concurrent use of alcohol, recreational drugs, and special diets 
o Concomitant use of medications (including nonprescription medicines and herbal 
and dietary supplements), plants, and mushrooms 
• Viral serologies  
• Creatine phosphokinase, haptoglobin, lactate dehydrogenase, and peripheral blood smear 
• Appropriate liver imaging if clinically indicated  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 59 of 63 • Appropriate blood sampling for pharmacokinetic analysis if this ha s not already been 
collected  
• Hepatology consult (liver biopsy may be considered in consultation with a hepatologist). 
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or are co nsidered stable by the Investigator. The 
“close observation period” is to continue for a minimum of 4 weeks after discontinuation of all 
investigational product(s) and protocol- required therapies.  
The potential drug-induced liver injury (DILI) event and additional information such as medical 
history, concomitant medications, and laboratory results must be captured in the corresponding 
electronic Case Report Form (eCRF).  
Important alternative causes for elevated AST/ALT and/or TBL values include, but are not  
limited to:  
• Hepatobiliary tract disease  
• Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein -Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus) 
• Right sided heart failure, hypotension, or any cause of hypoxia to the l iver causing 
ischemia  
• Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants, and mushrooms 
• Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler -Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
• Alpha-one antitrypsin deficiency 
• Alcoholic hepatitis  
• Autoimmune hepatitis  
• Wilson’s disease and hemochromatosis 
• Nonalcoholic fatty liver disease including steatohepatitis  
• Non-hepatic causes (eg , rhabdomylosis, hemolysis). 
Drug -induced Liver Injury Reporting and Additional Assessments  
Reporting 
To facilitate appropriate monitoring for signals of DILI, ie, cases of AST or ALT >3 x ULN and 
concurrent TBL >2 x ULN or INR >1.5 (for subjects not on anticoagulation therapy) without 
evidence of alternative cause of the elevations, require the following:  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 60 of 63 • The event is to be reported to the Sponsor as a serious adverse event within 24 hours of 
discovery or notification of the event (ie, before additional etiologic investigations have 
been concluded) 
• The appropri ate eCRF ca ptures information necessary to facilitate the evaluation of 
treatment -emergent liver abnormalities is to be completed and sent to the Sponsor. 
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse events if 
they meet the criteria for a serious adverse event defined in Appendix 1. 
 
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 61 of 63 Appendix  8: Schedule of Assessments  
Protocol CONFIDENTIAL  
Labcorp Drug Development Study: 8473020 Protocol Reference: 20200290 
Protocol Amendment 01, 24 August 2021  Page 63 of 63 f Prior and concomitant medication administration will be recorded beginning at informed consent. In addition, all Investigator -approved medications taken by a subject within 
30 days or 5 half -lives (whichever is longer) before Check-in for over -the-counter or prescription medications, and 30 days prior to enrollment for herbal medicines (eg, St. 
John’s wort), vitamins, and supplements, will be recorded on the subject’s electronic Case Report Form.  
g Performed in serum at Screeni ng and in urine at all other times for all females. A positive urine pregnancy test will be confirmed with a serum pregnancy test. 
h Performed in postmenopausal females only.  
i Electrocardiograms will be collected after the subject has rested in a supine p osition for at least 5 minutes, and will be obtained prior to the scheduled blood draws.  
j Supine blood pressure, supine heart rate, respiratory rate, and oral body temperature will be measured after the subject has been resting in the supine position for at least 
5 minutes.  
k Clinical chemistry fasted at least 8  hours.  
l eGFR will be calculated using the  Modified Renal Disease equation.  
m A full physical examination at Screening and Check -in and a symptom -directed physical examination at other timepoints . 
n The PK sample collected from predose  through 48 hours  postdose will have a sampling window of ±  30 minutes, samples collected at outpatient visits will have a sampling 
window of ±  48 hours . Times of all PK samples will be recorded to the nearest minute.  
o Dose administration of AMG 133 is to occur during the morning of Day 1 after an overnight fast of at least 10 hours.  
 
 
Protocol  CONFIDENTIAL  
Labcorp Drug Development Study : 8473020 Protocol Reference: 20200290 
 
Protocol Amendment 01, 24 August 2021 Page 1 of 2 Summary of Amended Protocol  Changes 
A Phase I, Open -label, Randomized, Parallel-arm, Single-dose Study to Evaluate the 
Safety, Tolerability, and Pharmacokinetics of AMG 133 Administered Subcutaneously in 
Healthy Japanese and Caucasian Subjects 
Protocol Status: Final  
Original Protocol Date: 09 August 2021 
Protocol Date: 24 August 2021 
Investigational Dru g: AMG 133 
 
Amgen Protocol Reference Number: 20200290 
Labcorp Drug Development Study : 8473020 
  
Sponsor: 
Amgen Inc.  
One Amgen Center Drive 
Thousand Oaks, California 91320, USA Study Site:  
Labcorp Drug Development  
3402 Kinsman Boulevard Madison, Wisconsin 53704, USA  
  
Sponsor Signatory: Prin cipal  Investigator: 
MD, MPH, MBE  
 
  
Information described herein is confidential and may be disclosed only with the express 
written permission of the Sponsor. 
________________________________________ 
The primary change in this amendment is : 
1. to update the number of injections in the  mg dose group from   
Minor c
han
ges: 
1. The version number and date were updated throughout the protocol. 
